Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Ovarian Neoplasms | 95 | 2024 | 4875 | 7.020 |
Why?
|
CA-125 Antigen | 20 | 2024 | 280 | 4.680 |
Why?
|
Neoplasms, Glandular and Epithelial | 18 | 2017 | 487 | 2.390 |
Why?
|
Mucin-1 | 8 | 2024 | 539 | 2.300 |
Why?
|
Talc | 4 | 2022 | 48 | 1.390 |
Why?
|
Membrane Proteins | 12 | 2022 | 7854 | 1.200 |
Why?
|
Carcinoma, Endometrioid | 5 | 2019 | 276 | 1.080 |
Why?
|
Cystadenocarcinoma, Serous | 8 | 2023 | 475 | 1.050 |
Why?
|
Postmenopause | 5 | 2023 | 2503 | 1.030 |
Why?
|
Menopause | 4 | 2023 | 1640 | 0.970 |
Why?
|
Case-Control Studies | 51 | 2024 | 22041 | 0.900 |
Why?
|
Parity | 8 | 2024 | 925 | 0.870 |
Why?
|
Nutrition Surveys | 4 | 2024 | 1727 | 0.780 |
Why?
|
Analgesics, Non-Narcotic | 1 | 2024 | 370 | 0.740 |
Why?
|
Acetaminophen | 2 | 2024 | 553 | 0.730 |
Why?
|
Adenocarcinoma, Mucinous | 4 | 2019 | 517 | 0.690 |
Why?
|
Mexican Americans | 1 | 2021 | 165 | 0.690 |
Why?
|
Genitalia, Female | 2 | 2019 | 147 | 0.650 |
Why?
|
Pelvic Inflammatory Disease | 1 | 2019 | 95 | 0.650 |
Why?
|
Leukocytes, Mononuclear | 3 | 2022 | 1828 | 0.630 |
Why?
|
Neoplasms, Cystic, Mucinous, and Serous | 3 | 2019 | 194 | 0.620 |
Why?
|
Therapeutic Irrigation | 1 | 2019 | 292 | 0.610 |
Why?
|
Polymorphism, Single Nucleotide | 22 | 2021 | 15766 | 0.590 |
Why?
|
Mucins | 2 | 2013 | 568 | 0.570 |
Why?
|
Female | 108 | 2024 | 391011 | 0.480 |
Why?
|
Contraception | 1 | 2018 | 348 | 0.470 |
Why?
|
Antibodies, Neoplasm | 2 | 2017 | 280 | 0.450 |
Why?
|
Homocysteine | 1 | 2017 | 640 | 0.450 |
Why?
|
Autoantibodies | 5 | 2018 | 2119 | 0.440 |
Why?
|
Cystadenoma, Serous | 1 | 2014 | 100 | 0.440 |
Why?
|
Mastitis | 1 | 2013 | 43 | 0.440 |
Why?
|
Middle Aged | 67 | 2024 | 220175 | 0.430 |
Why?
|
Genetic Predisposition to Disease | 18 | 2019 | 17766 | 0.430 |
Why?
|
Parturition | 1 | 2017 | 445 | 0.430 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 2024 | 2494 | 0.390 |
Why?
|
Estrogen Replacement Therapy | 4 | 2020 | 1207 | 0.390 |
Why?
|
Risk Factors | 39 | 2024 | 74269 | 0.380 |
Why?
|
Logistic Models | 16 | 2024 | 13311 | 0.370 |
Why?
|
Telomere | 2 | 2020 | 934 | 0.370 |
Why?
|
Telomerase | 2 | 2016 | 747 | 0.370 |
Why?
|
Antibodies | 2 | 2022 | 2424 | 0.360 |
Why?
|
Puerperal Disorders | 1 | 2013 | 300 | 0.360 |
Why?
|
Menstrual Cycle | 4 | 2017 | 536 | 0.350 |
Why?
|
Humans | 112 | 2024 | 760261 | 0.340 |
Why?
|
Lymphocytes | 2 | 2017 | 2612 | 0.340 |
Why?
|
Mumps | 1 | 2010 | 71 | 0.340 |
Why?
|
Polycystic Ovary Syndrome | 3 | 2019 | 378 | 0.330 |
Why?
|
Gene Expression Regulation, Neoplastic | 6 | 2018 | 8498 | 0.330 |
Why?
|
C-Reactive Protein | 2 | 2021 | 3822 | 0.330 |
Why?
|
New England | 5 | 2021 | 1045 | 0.320 |
Why?
|
Antigen-Antibody Complex | 1 | 2010 | 513 | 0.320 |
Why?
|
Ovariectomy | 1 | 2011 | 611 | 0.320 |
Why?
|
Endometriosis | 3 | 2022 | 871 | 0.320 |
Why?
|
Dysmenorrhea | 2 | 2021 | 98 | 0.310 |
Why?
|
Adenocarcinoma, Clear Cell | 3 | 2019 | 218 | 0.310 |
Why?
|
Breast Neoplasms | 8 | 2018 | 21065 | 0.300 |
Why?
|
New Hampshire | 3 | 2016 | 173 | 0.290 |
Why?
|
Adult | 43 | 2024 | 219847 | 0.290 |
Why?
|
Genetic Loci | 4 | 2017 | 2618 | 0.280 |
Why?
|
Aged | 37 | 2024 | 168995 | 0.280 |
Why?
|
Age Factors | 8 | 2021 | 18415 | 0.280 |
Why?
|
Inflammation | 4 | 2021 | 10757 | 0.280 |
Why?
|
Ovulation | 1 | 2007 | 181 | 0.260 |
Why?
|
Flavonoids | 1 | 2009 | 444 | 0.260 |
Why?
|
Alleles | 5 | 2017 | 6900 | 0.260 |
Why?
|
Hysterectomy | 1 | 2011 | 901 | 0.250 |
Why?
|
Early Detection of Cancer | 6 | 2019 | 3215 | 0.250 |
Why?
|
Risk | 11 | 2021 | 9629 | 0.240 |
Why?
|
Neutrophils | 2 | 2017 | 3770 | 0.240 |
Why?
|
Odds Ratio | 9 | 2024 | 9712 | 0.240 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2016 | 2927 | 0.230 |
Why?
|
MicroRNAs | 2 | 2017 | 3784 | 0.220 |
Why?
|
Cryptorchidism | 1 | 2024 | 151 | 0.220 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 3333 | 0.220 |
Why?
|
Carcinoma | 2 | 2022 | 2334 | 0.220 |
Why?
|
Genotype | 13 | 2019 | 12959 | 0.220 |
Why?
|
Area Under Curve | 5 | 2017 | 1635 | 0.210 |
Why?
|
Office Visits | 1 | 2007 | 597 | 0.210 |
Why?
|
Neoplasm Metastasis | 1 | 2013 | 4891 | 0.210 |
Why?
|
Proportional Hazards Models | 10 | 2021 | 12532 | 0.200 |
Why?
|
Endometrial Neoplasms | 1 | 2011 | 1361 | 0.200 |
Why?
|
Progestins | 2 | 2021 | 303 | 0.190 |
Why?
|
Sweden | 1 | 2024 | 1381 | 0.190 |
Why?
|
Genome-Wide Association Study | 11 | 2021 | 12602 | 0.190 |
Why?
|
Gold | 2 | 2022 | 485 | 0.190 |
Why?
|
Decision Support Techniques | 1 | 2011 | 2002 | 0.180 |
Why?
|
Physical Examination | 1 | 2007 | 1244 | 0.180 |
Why?
|
Genetic Association Studies | 7 | 2019 | 2716 | 0.180 |
Why?
|
Sex Hormone-Binding Globulin | 1 | 2023 | 546 | 0.180 |
Why?
|
Young Adult | 12 | 2024 | 58673 | 0.180 |
Why?
|
Powders | 1 | 2020 | 80 | 0.180 |
Why?
|
Microscopy, Electron, Scanning | 2 | 2019 | 941 | 0.180 |
Why?
|
Monocytes | 2 | 2022 | 2574 | 0.180 |
Why?
|
Medroxyprogesterone Acetate | 1 | 2021 | 155 | 0.180 |
Why?
|
Prognosis | 12 | 2021 | 29636 | 0.180 |
Why?
|
Contraceptives, Oral, Hormonal | 2 | 2019 | 190 | 0.170 |
Why?
|
Lymphocyte Count | 1 | 2022 | 780 | 0.170 |
Why?
|
Genitalia | 1 | 2020 | 113 | 0.170 |
Why?
|
Intrauterine Devices | 1 | 2021 | 114 | 0.170 |
Why?
|
Mendelian Randomization Analysis | 4 | 2019 | 989 | 0.170 |
Why?
|
Mastocytosis, Systemic | 1 | 2021 | 102 | 0.170 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 4 | 2024 | 3804 | 0.170 |
Why?
|
Gonadal Steroid Hormones | 1 | 2023 | 701 | 0.160 |
Why?
|
Pregnancy | 8 | 2024 | 29725 | 0.160 |
Why?
|
Platelet Count | 1 | 2022 | 777 | 0.160 |
Why?
|
Recreation | 2 | 2016 | 120 | 0.160 |
Why?
|
Breast Feeding | 2 | 2020 | 1356 | 0.160 |
Why?
|
Natural Killer T-Cells | 1 | 2022 | 311 | 0.160 |
Why?
|
Thymidylate Synthase | 1 | 2018 | 72 | 0.160 |
Why?
|
Glucuronosyltransferase | 1 | 2019 | 130 | 0.160 |
Why?
|
Genital Neoplasms, Female | 1 | 2024 | 538 | 0.160 |
Why?
|
Perineum | 1 | 2019 | 209 | 0.150 |
Why?
|
Pelvic Neoplasms | 1 | 2020 | 248 | 0.150 |
Why?
|
RNA, Antisense | 1 | 2018 | 136 | 0.150 |
Why?
|
A Kinase Anchor Proteins | 1 | 2018 | 52 | 0.150 |
Why?
|
Pelvis | 2 | 2019 | 743 | 0.150 |
Why?
|
Oligomenorrhea | 1 | 2017 | 42 | 0.150 |
Why?
|
Antigens, Neoplasm | 3 | 2018 | 1999 | 0.150 |
Why?
|
beta-Endorphin | 1 | 2017 | 43 | 0.140 |
Why?
|
Monomeric GTP-Binding Proteins | 1 | 2018 | 200 | 0.140 |
Why?
|
Receptor, Melanocortin, Type 2 | 1 | 2016 | 9 | 0.140 |
Why?
|
Keratin-13 | 1 | 2016 | 11 | 0.140 |
Why?
|
Biotinidase | 1 | 2016 | 17 | 0.140 |
Why?
|
Analgesics | 2 | 2021 | 1066 | 0.140 |
Why?
|
Glycomics | 1 | 2017 | 109 | 0.140 |
Why?
|
Receptors, Calcitriol | 1 | 2019 | 359 | 0.140 |
Why?
|
Contraceptives, Oral | 3 | 2024 | 554 | 0.130 |
Why?
|
Serum | 1 | 2017 | 211 | 0.130 |
Why?
|
Metal Nanoparticles | 1 | 2020 | 401 | 0.130 |
Why?
|
Estradiol | 1 | 2023 | 1932 | 0.130 |
Why?
|
Blood Cell Count | 1 | 2017 | 398 | 0.130 |
Why?
|
Abortion, Spontaneous | 1 | 2021 | 530 | 0.130 |
Why?
|
Prostatic Neoplasms | 3 | 2016 | 11341 | 0.130 |
Why?
|
Risk Assessment | 10 | 2023 | 24086 | 0.130 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2016 | 347 | 0.130 |
Why?
|
Hyperthyroidism | 1 | 2017 | 291 | 0.130 |
Why?
|
RNA Editing | 1 | 2016 | 151 | 0.130 |
Why?
|
Anticarcinogenic Agents | 1 | 2017 | 249 | 0.120 |
Why?
|
Receptors, Transforming Growth Factor beta | 1 | 2016 | 301 | 0.120 |
Why?
|
Abortion, Induced | 1 | 2021 | 460 | 0.120 |
Why?
|
Premenopause | 1 | 2019 | 1039 | 0.120 |
Why?
|
Microscopy, Fluorescence | 1 | 2022 | 2651 | 0.120 |
Why?
|
Germ Cells | 1 | 2018 | 635 | 0.120 |
Why?
|
Hormone Replacement Therapy | 1 | 2020 | 756 | 0.120 |
Why?
|
Massachusetts | 3 | 2016 | 8805 | 0.120 |
Why?
|
Epidemiologic Research Design | 1 | 2018 | 368 | 0.120 |
Why?
|
Menarche | 1 | 2017 | 529 | 0.110 |
Why?
|
Fluorescent Dyes | 1 | 2022 | 1914 | 0.110 |
Why?
|
Social Adjustment | 1 | 1996 | 632 | 0.110 |
Why?
|
Smoking | 3 | 2024 | 9070 | 0.110 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2018 | 493 | 0.110 |
Why?
|
Electrochemical Techniques | 1 | 2013 | 95 | 0.110 |
Why?
|
Pathology, Molecular | 1 | 2016 | 330 | 0.110 |
Why?
|
Killer Cells, Natural | 1 | 2022 | 2204 | 0.100 |
Why?
|
Prospective Studies | 7 | 2021 | 54263 | 0.100 |
Why?
|
Hypothyroidism | 1 | 2017 | 665 | 0.100 |
Why?
|
Testosterone | 1 | 2023 | 2469 | 0.100 |
Why?
|
Gene Amplification | 1 | 2017 | 1085 | 0.100 |
Why?
|
Serotonin | 1 | 2017 | 1041 | 0.100 |
Why?
|
Meta-Analysis as Topic | 4 | 2017 | 1375 | 0.100 |
Why?
|
Body Height | 1 | 2018 | 1570 | 0.100 |
Why?
|
Luminescent Measurements | 1 | 2013 | 377 | 0.100 |
Why?
|
Aged, 80 and over | 9 | 2021 | 58947 | 0.100 |
Why?
|
Carcinoma, Basal Cell | 1 | 2017 | 559 | 0.100 |
Why?
|
Alternative Splicing | 1 | 2016 | 1091 | 0.090 |
Why?
|
Nurses | 1 | 2021 | 2468 | 0.090 |
Why?
|
Genetic Variation | 2 | 2016 | 6540 | 0.090 |
Why?
|
Salpingectomy | 1 | 2011 | 48 | 0.090 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2021 | 2282 | 0.090 |
Why?
|
Colorectal Neoplasms | 1 | 2011 | 6855 | 0.090 |
Why?
|
Polysaccharides | 1 | 2017 | 1016 | 0.090 |
Why?
|
Polymerase Chain Reaction | 2 | 2012 | 6067 | 0.090 |
Why?
|
Habits | 1 | 2011 | 146 | 0.090 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2021 | 2874 | 0.090 |
Why?
|
Gene Expression Profiling | 5 | 2018 | 9388 | 0.090 |
Why?
|
Neoplasms | 3 | 2019 | 22066 | 0.090 |
Why?
|
Lymph Nodes | 2 | 2019 | 3491 | 0.090 |
Why?
|
Health Surveys | 1 | 2021 | 4061 | 0.090 |
Why?
|
ROC Curve | 3 | 2017 | 3568 | 0.090 |
Why?
|
Neoplastic Stem Cells | 1 | 2018 | 1347 | 0.090 |
Why?
|
Epididymal Secretory Proteins | 1 | 2010 | 12 | 0.090 |
Why?
|
Reproductive History | 1 | 2011 | 210 | 0.090 |
Why?
|
Environment | 2 | 2019 | 1118 | 0.090 |
Why?
|
Neoplasm Staging | 5 | 2023 | 11141 | 0.090 |
Why?
|
Pregnancy Complications | 1 | 2024 | 2940 | 0.090 |
Why?
|
Nanoparticles | 1 | 2022 | 1938 | 0.090 |
Why?
|
United States | 8 | 2024 | 72363 | 0.090 |
Why?
|
beta-Defensins | 1 | 2010 | 59 | 0.090 |
Why?
|
Leukocyte Count | 1 | 2014 | 1600 | 0.090 |
Why?
|
Pancreatic Neoplasms | 2 | 2018 | 5333 | 0.080 |
Why?
|
Quantitative Trait Loci | 4 | 2018 | 2101 | 0.080 |
Why?
|
Apigenin | 1 | 2009 | 17 | 0.080 |
Why?
|
Cell Lineage | 1 | 2018 | 2525 | 0.080 |
Why?
|
Exercise | 2 | 2016 | 5783 | 0.080 |
Why?
|
Microscopy, Polarization | 2 | 2019 | 89 | 0.080 |
Why?
|
Flavones | 1 | 2009 | 68 | 0.080 |
Why?
|
MAP Kinase Kinase Kinase 1 | 1 | 2009 | 56 | 0.080 |
Why?
|
Homozygote | 1 | 2014 | 1786 | 0.080 |
Why?
|
Actins | 1 | 2016 | 2049 | 0.080 |
Why?
|
Adolescent | 7 | 2021 | 87747 | 0.080 |
Why?
|
Cohort Studies | 7 | 2018 | 41317 | 0.080 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2009 | 208 | 0.070 |
Why?
|
Models, Theoretical | 1 | 2019 | 3561 | 0.070 |
Why?
|
Survival Rate | 5 | 2021 | 12806 | 0.070 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2015 | 1729 | 0.070 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2017 | 2823 | 0.070 |
Why?
|
Social Class | 1 | 2016 | 2005 | 0.070 |
Why?
|
Comorbidity | 3 | 2021 | 10552 | 0.070 |
Why?
|
Linear Models | 1 | 2017 | 5876 | 0.070 |
Why?
|
DNA, Neoplasm | 1 | 2012 | 1745 | 0.070 |
Why?
|
Lung Neoplasms | 1 | 2011 | 13249 | 0.070 |
Why?
|
Vitamin D | 2 | 2019 | 3293 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 2 | 2023 | 6545 | 0.070 |
Why?
|
Social Support | 1 | 1996 | 2145 | 0.070 |
Why?
|
Tumor Suppressor Proteins | 1 | 2016 | 2804 | 0.070 |
Why?
|
Blood Platelets | 1 | 2017 | 2522 | 0.070 |
Why?
|
Arthritis, Rheumatoid | 1 | 2021 | 3763 | 0.060 |
Why?
|
Biological Specimen Banks | 1 | 2011 | 776 | 0.060 |
Why?
|
Survival Analysis | 2 | 2017 | 10185 | 0.060 |
Why?
|
Age Distribution | 1 | 2011 | 2893 | 0.060 |
Why?
|
Alcohol Drinking | 1 | 2018 | 4012 | 0.060 |
Why?
|
Diagnosis, Differential | 1 | 2020 | 12968 | 0.060 |
Why?
|
DNA Methylation | 1 | 2018 | 4374 | 0.060 |
Why?
|
Sterilization, Tubal | 1 | 2024 | 80 | 0.060 |
Why?
|
Algorithms | 2 | 2022 | 13967 | 0.060 |
Why?
|
Environmental Exposure | 1 | 2019 | 4404 | 0.060 |
Why?
|
Heart Diseases | 1 | 2017 | 2809 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2016 | 10829 | 0.060 |
Why?
|
Antigens, Tumor-Associated, Carbohydrate | 1 | 2024 | 136 | 0.060 |
Why?
|
Microfilament Proteins | 1 | 2009 | 1134 | 0.060 |
Why?
|
Mutation | 3 | 2017 | 29950 | 0.050 |
Why?
|
Proteins | 1 | 2018 | 6030 | 0.050 |
Why?
|
Boston | 2 | 2007 | 9282 | 0.050 |
Why?
|
Estrogens | 2 | 2022 | 1520 | 0.050 |
Why?
|
Child | 3 | 2024 | 79758 | 0.050 |
Why?
|
Proteomics | 1 | 2016 | 3810 | 0.050 |
Why?
|
Disease-Free Survival | 3 | 2017 | 6830 | 0.050 |
Why?
|
Cyclin E | 1 | 2022 | 157 | 0.050 |
Why?
|
Mental Health | 1 | 1996 | 3206 | 0.050 |
Why?
|
Immune Tolerance | 1 | 2011 | 2299 | 0.050 |
Why?
|
Nuclear Proteins | 1 | 2016 | 5793 | 0.050 |
Why?
|
Preoperative Care | 1 | 2010 | 2255 | 0.050 |
Why?
|
RNA, Messenger | 3 | 2022 | 12762 | 0.050 |
Why?
|
Chronic Disease | 2 | 2018 | 9283 | 0.050 |
Why?
|
Time Factors | 3 | 2017 | 40133 | 0.050 |
Why?
|
Longitudinal Studies | 1 | 2017 | 14482 | 0.040 |
Why?
|
Multivariate Analysis | 2 | 2016 | 12156 | 0.040 |
Why?
|
Bayes Theorem | 2 | 2019 | 2325 | 0.040 |
Why?
|
Follow-Up Studies | 4 | 2021 | 39254 | 0.040 |
Why?
|
Male | 9 | 2024 | 359413 | 0.040 |
Why?
|
Europe | 2 | 2017 | 3433 | 0.040 |
Why?
|
Disease Susceptibility | 2 | 2016 | 1791 | 0.040 |
Why?
|
Interviews as Topic | 1 | 2007 | 2656 | 0.040 |
Why?
|
Ki-67 Antigen | 1 | 2021 | 631 | 0.040 |
Why?
|
Women's Health | 2 | 2019 | 2057 | 0.040 |
Why?
|
Oncogene Proteins | 1 | 2022 | 721 | 0.040 |
Why?
|
Hydro-Lyases | 1 | 2018 | 93 | 0.040 |
Why?
|
Body Mass Index | 1 | 2016 | 12901 | 0.040 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2017 | 9274 | 0.040 |
Why?
|
Sensitivity and Specificity | 3 | 2018 | 14656 | 0.040 |
Why?
|
Polymorphism, Genetic | 1 | 2009 | 4286 | 0.040 |
Why?
|
Gene Knockout Techniques | 1 | 2021 | 803 | 0.040 |
Why?
|
Obesity | 2 | 2019 | 12915 | 0.040 |
Why?
|
Enkephalin, Methionine | 1 | 2017 | 26 | 0.040 |
Why?
|
Carbohydrate Sequence | 1 | 2017 | 410 | 0.040 |
Why?
|
Incidence | 2 | 2016 | 21378 | 0.040 |
Why?
|
Skin Neoplasms | 1 | 2017 | 5797 | 0.040 |
Why?
|
Fucose | 1 | 2017 | 122 | 0.040 |
Why?
|
Reproducibility of Results | 2 | 2011 | 20048 | 0.040 |
Why?
|
N-Acetylneuraminic Acid | 1 | 2017 | 174 | 0.040 |
Why?
|
Retrospective Studies | 4 | 2023 | 80301 | 0.030 |
Why?
|
Hypertension | 1 | 2017 | 8595 | 0.030 |
Why?
|
Telomere-Binding Proteins | 1 | 2017 | 119 | 0.030 |
Why?
|
Population Surveillance | 2 | 2017 | 2609 | 0.030 |
Why?
|
Geography | 1 | 2018 | 661 | 0.030 |
Why?
|
Uterus | 1 | 2019 | 651 | 0.030 |
Why?
|
Protein Array Analysis | 1 | 2017 | 401 | 0.030 |
Why?
|
Neoplasm, Residual | 1 | 2020 | 1008 | 0.030 |
Why?
|
Adrenocorticotropic Hormone | 1 | 2017 | 619 | 0.030 |
Why?
|
History, 21st Century | 1 | 2021 | 1576 | 0.030 |
Why?
|
Morphogenesis | 1 | 2018 | 740 | 0.030 |
Why?
|
Glycosylation | 1 | 2017 | 1097 | 0.030 |
Why?
|
Antibody Specificity | 1 | 2016 | 1061 | 0.030 |
Why?
|
Microarray Analysis | 1 | 2017 | 747 | 0.030 |
Why?
|
Antibodies, Monoclonal | 1 | 2010 | 9196 | 0.030 |
Why?
|
Data Mining | 1 | 2018 | 553 | 0.030 |
Why?
|
Child, Preschool | 2 | 2021 | 42034 | 0.030 |
Why?
|
Object Attachment | 1 | 1996 | 324 | 0.030 |
Why?
|
Personality Inventory | 1 | 1996 | 1018 | 0.030 |
Why?
|
History, 20th Century | 1 | 2021 | 2777 | 0.030 |
Why?
|
Models, Biological | 1 | 2009 | 9468 | 0.030 |
Why?
|
Australia | 1 | 1996 | 1288 | 0.030 |
Why?
|
Cell Line, Tumor | 2 | 2020 | 16905 | 0.020 |
Why?
|
BRCA2 Protein | 1 | 2017 | 797 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2018 | 15273 | 0.020 |
Why?
|
Delayed Diagnosis | 1 | 2016 | 463 | 0.020 |
Why?
|
Databases, Genetic | 1 | 2018 | 1739 | 0.020 |
Why?
|
Animals | 4 | 2016 | 167940 | 0.020 |
Why?
|
Organ Specificity | 1 | 2016 | 1955 | 0.020 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2017 | 1256 | 0.020 |
Why?
|
Diet | 1 | 2009 | 8008 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2018 | 2003 | 0.020 |
Why?
|
BRCA1 Protein | 1 | 2017 | 1146 | 0.020 |
Why?
|
Health Behavior | 1 | 2021 | 2621 | 0.020 |
Why?
|
Genetic Markers | 1 | 2016 | 2608 | 0.020 |
Why?
|
Epitopes | 1 | 2016 | 2506 | 0.020 |
Why?
|
Gene Frequency | 1 | 2016 | 3605 | 0.020 |
Why?
|
Enhancer Elements, Genetic | 1 | 2016 | 1356 | 0.020 |
Why?
|
Tacrolimus | 1 | 1993 | 730 | 0.020 |
Why?
|
Androgens | 1 | 2016 | 1289 | 0.020 |
Why?
|
Motor Activity | 1 | 2019 | 2687 | 0.020 |
Why?
|
Weight Gain | 1 | 2019 | 2347 | 0.020 |
Why?
|
Models, Genetic | 1 | 2018 | 3442 | 0.020 |
Why?
|
Regression Analysis | 1 | 2018 | 6361 | 0.020 |
Why?
|
Chromosome Mapping | 1 | 2016 | 4625 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2021 | 25928 | 0.020 |
Why?
|
Overweight | 1 | 2019 | 2421 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2016 | 1740 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2018 | 2368 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2016 | 3774 | 0.020 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2018 | 3601 | 0.020 |
Why?
|
Psychometrics | 1 | 1996 | 3049 | 0.020 |
Why?
|
Computational Biology | 1 | 2018 | 3504 | 0.020 |
Why?
|
Self Report | 1 | 2017 | 3707 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2021 | 10434 | 0.020 |
Why?
|
Registries | 1 | 2021 | 8449 | 0.020 |
Why?
|
Aspirin | 1 | 2017 | 3365 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 1993 | 2378 | 0.010 |
Why?
|
Apoptosis | 1 | 2020 | 9497 | 0.010 |
Why?
|
Computer Simulation | 1 | 2018 | 6210 | 0.010 |
Why?
|
Signal Transduction | 2 | 2018 | 23363 | 0.010 |
Why?
|
Hypoglycemic Agents | 1 | 2017 | 3149 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2016 | 3613 | 0.010 |
Why?
|
Mice | 1 | 2010 | 81216 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2017 | 11064 | 0.010 |
Why?
|
Transcription Factors | 1 | 2022 | 12100 | 0.010 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2016 | 3076 | 0.010 |
Why?
|
Insulin | 1 | 2017 | 6592 | 0.010 |
Why?
|
Liver Transplantation | 1 | 1993 | 2317 | 0.010 |
Why?
|
Phenotype | 1 | 2018 | 16543 | 0.010 |
Why?
|
Heart Transplantation | 1 | 1993 | 3217 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2017 | 5884 | 0.010 |
Why?
|
Mesocricetus | 1 | 1993 | 252 | 0.010 |
Why?
|
Splenectomy | 1 | 1993 | 391 | 0.010 |
Why?
|
Antilymphocyte Serum | 1 | 1993 | 482 | 0.010 |
Why?
|
Mycophenolic Acid | 1 | 1993 | 343 | 0.010 |
Why?
|
Immunoglobulin A | 1 | 1993 | 978 | 0.010 |
Why?
|
Cricetinae | 1 | 1993 | 2427 | 0.010 |
Why?
|
Drug Synergism | 1 | 1993 | 1755 | 0.000 |
Why?
|
Fluorescent Antibody Technique | 1 | 1993 | 2473 | 0.000 |
Why?
|
Antibody Formation | 1 | 1993 | 1400 | 0.000 |
Why?
|
Biphenyl Compounds | 1 | 1993 | 988 | 0.000 |
Why?
|
Immunoglobulin M | 1 | 1993 | 1529 | 0.000 |
Why?
|
Cyclophosphamide | 1 | 1993 | 2220 | 0.000 |
Why?
|
Drug Therapy, Combination | 1 | 1993 | 6499 | 0.000 |
Why?
|
Graft Survival | 1 | 1993 | 3793 | 0.000 |
Why?
|
Immunosuppressive Agents | 1 | 1993 | 4168 | 0.000 |
Why?
|
Graft Rejection | 1 | 1993 | 4423 | 0.000 |
Why?
|
Rats | 1 | 1993 | 23695 | 0.000 |
Why?
|